Localized Sinus Drug Delivery

Intersect ENT has developed the PROPEL family of dissolvable implants for chronic sinusitis patients undergoing sinus surgery; the first and only sinus surgery product backed by Level 1-A evidence which improves sinus surgery outcomes.1

PROPEL Mometasone Furoate Logo - Localized Sinus Drug DeliveryPROPEL sinus implants are the first of a new category of products offering localized, controlled drug delivery directly to the sinus tissue. The spring-like implant is inserted by a physician to maintain the surgical opening, prop open the ethmoid sinus, and gradually deliver an advanced corticosteroid (mometasone furoate) with anti-inflammatory properties directly to the sinus lining as the implant dissolves.

PROPEL sinus implants are clinically proven to reduce post operative ethmoid interventions following surgery.1 The results show improved outcomes including improved post-operative outcomes, reducing the need for systemic steroids and additional surgical procedures, such as adhesion lysis.1

PROPEL post-surgical sinus drug delivery stent product image

PROPEL Sinus Implant Meta-Analysis:
Safety and Effectiveness Following Ethmoid Sinus Surgery

PROPEL provides meaningful benefits to patients: PROPEL maintains the opening created during surgery by reducing post-operative scarring, inflammation, polyposis and middle turbinate lateralization. Reducing such scarring and inflammation is essential to improve long-term outcomes and reduce the need for revision surgery.2,3

PROPEL sinus implant vs control safety and effectiveness

PROPEL Sinus Implant Product Details

  • Indicated for the Ethmoid Sinus
  • Springlike Expansion for Mechanical Spacing
  • 23mm Nominal Length
PROPEL localized sinus drug delivery product image

Learn More About
PROPEL Sinus Implants

We have compiled resources to help physicians and patients better understand how the PROPEL steroid-releasing implant works to improve sinus surgery outcomes.

1Han JK, Marple BF, Smith TL, et al. Int Forum Allergy Rhinol. 2012; 2:271-279.
3Kennedy DW, Wright ED, Goldberg AN. Laryngoscope. 2000; 110(S94):29-31.
4Kennedy DW. Expert Review of Respiratory Medicine. 2012; 6(5):493-498.

The PROPEL sinus implants are intended for use after sinus surgery to maintain patency and to locally deliver steroid to the sinus mucosa: PROPEL for use in the ethmoid sinus, PROPEL Mini for use in the ethmoid sinus and frontal sinus opening, and PROPEL Contour for use in the frontal and maxillary sinus ostia. The implants are intended for use in patients ≥18 years of age. Contraindications include patients with intolerance to mometasone furoate (MF) or a hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implants in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For complete prescribing information see IFU at www.IntersectENT.com. Rx only.

The PROPEL® implant, delivery system, and/or the use of the PROPEL® implant/delivery system in a method may be covered by one or more U.S. and/or foreign patents, including U.S. Patent Nos. 7,544,192, 7,662,141, 7,662,142, 7,713,255, 7,951,130, 7,951,131, 7,951,133, 8,109,918, 8,535,707, 8,585,730, 8,585,731, and 8,763,222. Other patent applications are pending. This page is intended to serve as notice under 35 U.S.C. § 287(a). Other patent applications are pending. This page is intended to serve as notice under 35 U.S.C. § 287(a).